Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX030 (oral cedazuridine + azacitidine) versus subcutaneous azacitidine in MDS/CMML/AML
2024-515098-93-00Phase 3Authorised
- Sponsor
- Taiho Oncology
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of cedazuridine + azacitidine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) (2 arms), sponsored by Taiho Oncology. Primary endpoint: azacitidine exposure AUC ratio. Planned start May 2025; status: authorised.
02
Drugs
cedazuridine + azacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-515098-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515098-93-00.